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Abstract: Nitric oxide (NO) has been implicated in several cellular processes as a 
signaling molecule and also as a source of reactive nitrogen species (RNS). NO is 
produced by three isoenzymes called nitric oxide synthases (NOS), all present in skeletal 
muscle. While neuronal NOS (nNOS) and endothelial NOS (eNOS) are isoforms 
constitutively expressed, inducible NOS (iNOS) is mainly expressed during inflammatory 
responses. Recent studies have demonstrated that NO is also involved in the mitochondrial 
biogenesis pathway, having PGC-1α as the main signaling molecule. Increased NO 
synthesis has been demonstrated in the sarcolemma of skeletal muscle fiber and NO can 
also reversibly inhibit cytochrome c oxidase (Complex IV of the respiratory chain). 
Investigation on cultured skeletal myotubes treated with NO donors, NO precursors or 
NOS inhibitors have also showed a bimodal effect of NO that depends on the concentration 
used. The present review will discuss the new insights on NO roles on mitochondrial 
biogenesis and function in skeletal muscle. We will also focus on potential therapeutic 
strategies based on NO precursors or analogs to treat patients with myopathies and 
mitochondrial deficiency. 
Keywords: nitric oxide; nitric oxide synthase; mitochondrial biogenesis; mitochondria; 
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1. Introduction 
Nitric oxide (NO·) has been studied in different areas of biomedical sciences due to its multiple 
roles, acting as signaling molecule in several cellular processes and as a free radical, involved in 
oxidative damage. A simple search in PubMed (12/01/2012) using the term “nitric oxide” and 
“mitochondria” resulted in 2733 articles and 1940 articles were published in the last decade. These 
data show the great importance of this molecule in biomedical sciences with studies in different areas, 
aiming the elucidation of physiological pathways, pathogenesis and treatment strategies based on NO 
function. In fact, the use of NO in clinical practice is not new. Sodium nitroprusside, an NO donor, is a 
good example of clinical application that is still in use as a potent vasodilator, resulting in a rapid 
control of dangerous levels of arterial hypertension [1]. With the recent discoveries of other functions 
of NO, novel treatments may be developed in different areas of medicine, including treatment of 
mitochondrial abnormalities.  
NO is involved in different signaling pathways in mitochondria, including control of mitochondrial 
respiration, apoptosis, free radical generation and more recently, mitochondrial biogenesis [2–5]. The 
present review will discuss the new insights of the roles of NO on mitochondrial biogenesis and function 
in skeletal muscle. We will also focus on potential therapeutic strategies based on NO precursors or 
analogs to treat patients with myopathies and other diseases associated with mitochondrial deficiency. 
2. NO and Nitric Oxide Synthase 
NO is a gaseous, inorganic, uncharged, diatomic molecule and a free radical with one unpaired 
electron in its external orbital [3,6]. It is highly lipophilic and diffusible, so NO can pass through 
multiple cell membranes to reach its final target at some distance from the sites of NO synthesis [7]. 
Considering its very short half-life, less than 5 s, NO cannot be stored in free form and is generally 
synthesized on demand with specific biological effects [7]. This molecule is produced by three 
isoforms of NO synthases (NOS): neuronal NOS (nNOS, EC 1.14.13.39), endothelial NOS (eNOS, EC 
1.14.13.39) and inducible NOS (iNOS, EC 1.14.13.39). These isoforms were originally named because 
of the tissues from where they were first purified (neuronal and endothelial) and the mode of activation 
in the case of iNOS; but because they were also identified in several other cells, these denominations 
became inappropriate. Despite the proposal of other nomenclatures (numerical and descriptive) [8] the 
original denominations are still used. In the numerical nomenclature nNOS is type I, iNOS is type II 
and eNOS is type III enzyme. In the descriptive nomenclature the dependence of Ca2+ is indicated by a 
letter “c”, such as ncNOS and ecNOS, for neuronal and endothelial isoforms, respectively. These 
differences in nomenclature cause great confusion in the literature but in this review, we will only 
consider the original denominations: nNOS, eNOS and iNOS. All three types of NOS are expressed in 
skeletal muscle [9]. 
NOS uses molecular oxygen to oxidize the guanidinium nitrogen atom of L-arginine to produce NO 
and L-citrulline [6]. Two isoforms, nNOS and eNOS, are constitutive and regulated by the interaction 
of Ca2+ with calmodulin [6]. On the other hand, iNOS is usually only expressed during defense 
mechanisms against infections or inflammation [8] and it is not regulated by Ca2+ because it forms a 
complex with calmodulin at very low concentrations of Ca2+ [2]. Four co-factors are required for NO 
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synthesis: tetrahydrobiopterin (BH4), flavin adenine dinucleotide (FAD), flavin monucleotide (FMN) 
and nicotinamide adenine dinucleotide phosphate (NADPH) [3]. 
Although all three NOS isoforms are products of different genes, they have similar structure with 
50%–60% sequence identity [7] and are only active as dimer [10] (Figure 1). Each subunit of this 
dimeric complex is composed by two domains, oxygenase and reductase domains. The oxygenase 
domain contains the binding sites for L-arginine, BH4 and heme (Fe) and the reductase domain binds 
to FMN, FAD, NADPH and calmodulin [7,10,11]. Both subunits are attached at the oxygenase 
domain, forming the dimeric conformation. In skeletal muscle, the nNOS isoform has an additional 
250 amino acid N-terminal sequence, the PDZ motif, that target the enzyme to the sarcolemma, in 
skeletal muscle [7]. Myristoylation and palmitoylation sites are typically present in eNOS N-terminal. 
Acylation by myristate and palmitate is required for the subcellular localization of eNOS in the 
caveolae of endothelial cells [11]. 
Figure 1. Schematic diagram illustrating the organization of human nitric oxide synthases. 
(a) Schematic figure showing the dimeric conformation of nitric oxide synthases (NOS) 
with both subunits attached at the oxygenase domains (green); (b) Main structure 
differences between the three types of NOS isoforms. PDZ domain is typically present in 
neuronal NOS (nNOS), the presence of myristoylation (Myr) and palmitoylation (Palm) 
sites are specific to endothelial NOS (eNOS). All isoforms the oxygenase domain contains 
binding sites for L-arginine (Arg), Heme and tetrahydrobiopterin (BH4) while the reductase 
domain binds to calmodulin (CAM), FMN, FAD and NADPH. iNOS = induced NOS. 
 
Since the first isolation and characterization of NOS [12], several splice variants have been 
discovered [13,14]. nNOS is encoded by the gene NOS1 localized in chromosome 12q24.22, contains 
29 exons and has at least ten transcript variants [15]. The classical isoform (nNOSα) is predominantly 
found in neuronal cells, contains both exon 2, which is responsible for the catalytic activity of the 
enzyme and the PDZ domain, which interacts with membrane proteins [16]. nNOSβ and nNOSδ lack 
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the PDZ domain, maintain the catalytic domains and have different exon 1 sequence [15]. Another 
variant, nNOSμ, contains an additional in-frame exon between exon 16 and 17. Primarily found in 
mouse skeletal and cardiac muscles, it was later found in other human organs, such as aorta, bladder, 
colon, corpus cavernosum and placenta [17]. A human testis specific variant, TnNOS, which is 
analogue to the mouse nNOSδ, was also described and characterized with a shorter N-terminus [18].  
The isoform eNOS is encoded by the gene NOS3, located on chromosome 7q36; and highly 
expressed in intestine, parathyroid, placenta, ovary, kidney, platelet and myocyte [19,20]. There are 
three transcript variants, with shorter distinct-C-terminus due to alternate 3' exon and polyadenylation 
site, known as eNOS13A, eNOS13B and eNOS13C [21]. iNOS is encoded by the gene NOS2, located 
on chromosome 17q11.2 and is expressed in several cell types and tissue in response to inflammatory 
agents and cytokines [22]. In addition, NO can also be generated through non enzymatic sources, such 
as the reduction of nitrite to NO in disease states, such as ischemia, and under the acidic and highly 
reduced conditions [23]. 
2.1. Mitochondrial NOS 
The finding of co-localization of eNOS expression with mitochondrial markers in skeletal muscle, 
suggested a close relationship between eNOS and mitochondria [24]. In fact, using gold labeling and 
electron microscopy, immunoreactivity to eNOS was found in rat liver and brain mitochondria [25]. It 
was, therefore, hypothesized that a mitochondrial NOS (mtNOS) could be eNOS or another NOS  
with significant homology to this form [25]. The co-localization of eNOS and mitochondria was 
demonstrated in other studies, where immunoreactivity to eNOS was found associated to skeletal 
muscle mitochondria in skeletal muscle [26,27]. Actually, NO production by isolated mitochondria 
strongly suggested the existence of an mtNOS [28,29]. Lacza et al. confirmed the presence of NOS 
activity in liver, using the assay of conversion of L-arginine to citrulline and also found 
immunoreactivity to eNOS by Western blot and immuno-gold labeling with electron microscopy [30]. 
However, the same group was not able to confirm these results in a later study, when NOS activity  
and NO production were not detected in liver mitochondria [31]. They also identified specific 
immunoreactivity to nNOS, iNOS and eNOS in liver mitochondria obtained from nNOS, iNOS and 
eNOS knockout mice, excluding these isoforms as the mtNOS. Studies on this subject have been 
controversial because they are based on the presence of NOS activity, NO production or 
nitrite/peroxynitrite in isolated mitochondria from rat liver [28,32,33], PC12 (rat neuronal cells) and 
COS-1 (monkey fibroblasts) cells [34], porcine heart [35], rat kidney [36], rat heart [37]; while others 
do not confirm these findings in murine liver [31,38,39]. Other studies using different approaches have 
suggested that mtNOS might be eNOS [25,26,40], iNOS [32,33,35,37] or even nNOS [36,41–43]. 
These discrepancies can be explained by differences in methods of purification of mitochondrial 
fraction, specificity of the method of NOS detection and different tissue/cell sources. Studies with 
knockout mice have also given discrepant results [31,44]. Kanai et al. (2001) studied heart from 
knockout (nNOS −/−, iNOS −/− and eNOS −/−) mice and observed absence of mitochondrial NO 
production only in nNOS −/− knockout mice, indicating that nNOS should be the mtNOS, specifically 
the nNOSα variant, which was the gene knocked out in these mice [44]. Lacza et al., however, have 
not confirmed NO production in nNOS knockout mice [45]. 
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Only a few studies focused on the existence and identity of mtNOS in skeletal muscle [40,46]. In rat 
muscle, eNOS was localized in mitochondria by electron microscopy [40] which is supported by the 
findings of co-localization of eNOS with mitochondrial markers in rat [24] and human muscle fibers 
with mitochondrial proliferation [26,27]. Studying the insulin induced effects on NO synthesis in  
rat skeletal muscle, Finocchietto et al. showed an increased mitochondrial NO synthesis via Akt 
phosphorylation that was dimished in nNOS silenced rat muscle. Based on these results they  
concluded that the mtNOS would be a variant of nNOS that could be subjected to pos-translational  
modifications [47]. It was also suggested that nNOS could be translocated to mitochondria but with 
unclear mechanisms [48]. Recently, Aguirre et al. [46] tried to identify the nature of mtNOS 
performing a study on skeletal muscle mitochondria of mice injected with lipopolysaccharide (LPS), 
considering that mtNOS expression was reported to increase in response to endotoxin [49]. The 
authors observed that in the presence of a NOS substrate, mitochondria from LPS treated mice had 
lower respiration rate, which was prevented by a NOS inhibitor. Because they could not find the 
expression of the known iNOS, they suggested that the mtNOS could be an endotoxin-inducible NOS 
but distinct from iNOS and the other cytosolic isoforms. In skeletal muscle there are some evidences 
suggesting that, at least in this tissue, eNOS or a similar variant may be the mtNOS, but more 
clarification is still needed. 
2.2. NOS Isoforms in Skeletal Muscle 
In skeletal muscle, nNOS and eNOS isoforms are expressed constitutively while iNOS is only 
expressed during inflammatory responses [9,50]. Each NOS isoform has a specific localization in 
different compartments of muscle fibers. The nNOS isoform is considered the main source of NO in 
skeletal muscle, however it is not the same isoform expressed in brain. A splice variant is expressed in 
skeletal muscle, nNOSµ, characterized by an insertion between exon 16 and 17, encoding a  
34-aminoacid segment [51]. This isoform is located on the sarcolemma (muscle membrane) [26,27], 
with higher activity in type II (fast twitch) fibers and linked to the dystrophin complex [26,52,53]. 
nNOS expression in the sarcoplasm was also reported in type I and II fibers, but more intense in type I 
fibers [54]. It was demonstrated that nNOSµ is also present in soluble fractions of gastrocnemius 
muscle homogenates in mice, showing the existence of a soluble cytoplasmic nNOSµ [55]. Studies 
with mice with reduced sarcolemmal nNOS but preserved soluble nNOS show that NO produced by 
sarcolemmal nNOS acts in the regulation of α-adrenergic vasoconstriction and blood supply in 
contracting skeletal muscle [55,56]. In the absence of sarcolemmal nNOS there is a considerable 
decrease in the blood supply during electrically evoked muscle contraction in mice [55], which 
demonstrates the important role of this isoform in exercise capacity. However, when sarcolemmal 
nNOS is absent, cytoplasmic nNOSµ is not able to compensate the NO deficiency [55]. Another nNOS 
splice variant, nNOSß, was recently identified and localized in the Golgi complex [56]. The loss of 
nNOSµ and ß in genetically modified mice showed disruption of the microtubule cytoskeleton and 
abnormal mitochondrial morphology, suggesting that both splice variants have an important role in 
maintaining normal mitochondrial health [56]. The function of the cytoplasmic nNOSµ remains unclear.  
Expression of eNOS is primarily found in endothelial cells of vessels and microvessels [54]  
but sarcoplasmic expression has also been reported [26,27]. This pattern is confirmed by  
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NADPH diaphorase histochemistry, which is considered an indirect method to evaluate NOS  
activity [26,27,53]. Abnormalities in specific isoforms such as nNOS and eNOS have been reported in 
muscle diseases with mitochondrial deficiencies [26,27], indicating that specific NOS activities and 
expression may be involved in the pathogenesis of these diseases. Increased nNOS activity and 
expression were observed in muscle fibers with mitochondrial proliferation, suggesting that it is related 
to mitochondrial biogenesis [27]. However, the exact mechanisms involved in these abnormalities  
are not clear. 
3. Regulation of NOS 
Due to the various physiological roles, specific tissue expression and different isoforms, it is 
reasonable to believe that the regulatory mechanisms controlling NOS activity, expression and 
localization are very complex and multifactorial. All types of NOS are transcriptionally modulated and 
exhibit inducible and constitutive patterns of expression in different tissue environments [7]. The 
mechanisms of regulation can be summarized in alternative mRNA splicing, protein-protein interactions 
(e.g., to Ca2+/calmodulin complex, PDZ domains, PIN, caveolin-1 and 3, Hsp90, ENAP-1, kalirin), 
covalent modifications (phosphorylation, myristoylation, palmitoylation) and redox signaling [7,11,57]. 
These regulatory mechanisms control the expression, localization and activity of NOS.  
The expression of nNOS and eNOS in specific tissues is controlled in some cases by alternate 
mRNA splicing, as in the case of TnNOS, expressed in testis [18,58], while the presence of a 220 
aminoacid sequence in the N-terminal of nNOS, containing the PDZ domain, targets nNOS to the brain 
and skeletal muscle [16]. In skeletal muscle, PDZ domain interactions mediate binding to syntrophin, a 
dystrophin associated protein, localizing the muscle nNOS to the sarcolemmal membrane. When this 
complex is absent, such as in Duchenne muscular dystrophy, nNOS is not attached to the membrane 
and localizes in the cytosol [59].  
The processes of myristoylation and palmitoylation (acylation with the fatty acids myristate and 
palmitate) are required for the proper localization of enzyme in the caveolae of endothelial  
cells [60,61]. In cardiac myocytes, eNOS is localized in plasmalemmal caveolae due to the process of 
palmitoylation [62]. Caveolae are microdomains of the plasmalemmal membrane and it is coated by 
proteins called caveolin. Caveolin 1 and 3 are negative regulator of eNOS and nNOS [63].  
The interaction between calmodulin and Ca2+ is required for nNOS and eNOS activity. However 
several proteins can interact and regulate the enzyme activity. The FMN-binding sub-domain can act 
as an enzyme inhibitor, by destabilizing calmodulin binding at low Ca2+ level. PIN, an 89-amino-acid 
protein that specifically interacts with the N-terminal of nNOS, has been associated with inhibition of 
the isoform activity [64,65], but it has also been argued that this inhibition may not be specific to 
nNOS [66]. The molecular chaperone Hsp90 increases eNOS activity [67] whereas kalirin, a cytosolic 
protein, inhibits iNOS by preventing dimer formation [68]. Structures such as BH4 and Zinc binding 
are not required for dimer formation but are important for stabilization of this structure, acting in the 
regulation of NOS activity [69]. Phosphorylation can have an inhibitory effect on nNOS activity while 
on eNOS the activity is increased [70–73]. 
The influence of redox signaling on NOS activity has been demonstrated for the endothelial 
isoform. ROS can affect eNOS through pos-translational modifications such as S-glutathionylation,  
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S-nitrosylation; H2O2-dependent activation or interactions affecting signaling pathways of eNOS 
activation [7,57,74]. The importance of S-glutathionylation in the regulation of endothelial function 
and vascular tone has been demonstrated by the finding of increased S-glutathionylation in 
hypertensive vessels, that was restored by thiol-specific reducing agents, which reverse this  
S-glutathionylation [75].  
S-glutathionylation induces a reversible uncoupling of eNOS, which during oxidative stress, could 
function to prevent irreversible oxidative damage of the thiols critical for eNOS function [76].  
S-nitrosylation of eNOS is an important mechanism of activity control. It was demonstrated that eNOS 
is constitutively S-nitrosylated in resting endothelial cells but with the addition of an eNOS agonist, 
eNOS is denitrosylated and then progressively renitrosylated, resuming its original level. An inverse 
relationship between eNOS activity and S-nitrosylation was also found in endothelial cells. These 
results show that eNOS S-nitrosylation leads to a decrease in enzyme activity [77]. S-nitrosylation is 
also a dynamic mechanism of control of NOS activity. Targeting of eNOS to cellular membranes, such 
as caveolae, was also demonstrated as a requirement of eNOS S-nitrosylation while when the enzyme 
location in the cytosol promotes denitrosylation [77,78]. Mass spectrometry analysis showed that the 
location of S-nitrosylation is the zinc-tetrathiolate of eNOS[78]. However the roles of these 
mechanisms on regulation of NOS isoforms in skeletal muscle are yet to be clarified. 
H2O2 is a key modulator of eNOS activation in vascular endothelial cells [79] and cardiac  
myocytes [80]. Using a highly sensitive fluorescent probe it was possible to demonstrate that low 
concentrations of H2O2 promote NO synthesis, through activation of eNOS by phosphorylation on 
multiple residues [80]. Comparing the effects of H2O2 treatment on cardiac myocytes from eNOSnull 
and nNOSnull, Sartoretto et al. found that H2O2 treatment effects were abolished in eNOSnull cells while 
nNOSnull myocytes H2O2 effects were maintained, suggesting that eNOS is the main source of H2O2 
induced NO synthesis [80]. Interestingly, Waypa et al. [81] demonstrated that H2O2 production  
in pulmonary smooth muscle cells under hypoxic conditions is increased in the mitochondrial 
intermembrane space but not in the matrix, which favours the idea of compartmentalized  
redox regulation. 
Signaling pathways of NOS activation can also be affected by redox modifications in several 
intermediaries (for review see [74]).  
4. NO and Mitochondrial Function 
NO diffuses from mitochondria to cytosol, as well as from cytosol to mitochondria, what is called 
mitochondria-cytosol NO cross-talk [82]. Through the interaction with other molecules or proteins, 
NO exerts its function on signaling physiological events or promoting cell damage (Figure 2). 
Nitrosative and oxidative modifications generally constitute redox-related signaling events in 
several physiological pathways or nitrosative/oxidative stress promoting mitochondrial damage [9]. 
NO can react to three types of targets: (a) molecular oxygen and superoxide anions; (b) transition 
metals such as heme iron and iron-sulfur centers; and (c) reduced thiols [83].  
The reaction of NO with molecular oxygen or superoxide anions generates low molecular weight NO 
derivatives that participate in electron transfer reactions, as retain redox activity [84]. The formation of 
peroxynitrite from the combination of NO and superoxide, however, mediates oxidative damage [9]. 
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Figure 2. The influence of NO on mitochondrial respiratory chain. The main site of 
inhibition of respiratory chain by NO is at complex IV (cytochrome c oxidase) by 
competition with oxygen. NO can also inhibits the electron transport chain at complex I 
(NADH dehydrogenase) and III (ubiquinol cytochrome c oxido reductase). The disturbance 
in the electron transport chain favors the formation of superoxide anions (O2−). The 
reaction between superoxide anions and NO, results in formation of peroxynitrite 
(ONOO−) inducing macromolecular damage and cell death.  
 
The reaction with transition metals represents a mechanism of NO buffering or regulation. Protein 
activity can be modulated through reversible reaction with transition metals and thiols [84]. The 
interaction of NO with heme iron of soluble glanylyl cyclase induces a conformational change 
activating this enzyme and increasing cyclic guanosine monophosphate (cGMP) levels [84,85]. This 
increase activates cGMP-dependent protein kinases or cGMP-gated ion channels, characterizing the 
NO mediate physiological actions [82]. 
NO can also interact with other heme-containing proteins, such as, cytochrome c oxidase, or with 
iron-sulfur clusters present in complex I of the respiratory chain, both promoting enzyme inhibition [9].  
NO reacts with protein thiol (RSH, RS-) via S-nitrosylation to form RS–NO groups, this reaction  
is reversed by NO transfer to other sulphur centers. S-nitrosylation of glutathione and other  
non-regulatory thiols can act as NO buffering and regulate protein function by altering conformation, 
by accelerating disulphide formation, or by influencing the reactivity of nearby metal centers [86].  
Finocchietto et al. [47] demonstrated the role of NO on glucose metabolism. These studies 
demonstrated that insulin increased muscle oxidative rate via mitochondrial NO, resulting in decline  
of mitochondrial O2 uptake. In the absence of NO, mitochondrial O2 uptake is completely released 
leading to a preferential oxidation of glucose to CO2 and H2O, while in the presence of NO, glucose 
utilization is delivered to glycogen synthesis.  
4.1. Control of Mitochondrial Respiration 
NO affects mitochondrial function in many ways. Because of its vascular smooth muscle relaxing 
effect, NO regulates blood flow to skeletal muscle fiber, facilitating the supply of respiratory substrates 
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to mitochondria [9]. NO also regulates binding and release of O2 from hemoglobin in red blood  
cells [87], thereby regulating oxygen delivery to tissues and consequently the O2 supply to the 
mitochondria [88]. The classical concept of control of mitochondrial respiration is based on the 
mitochondrial metabolic states, which is controlled by ADP availability [89]. In state 4, there is 
availability of respiratory substrate but not of ADP, while in state 3, both respiratory substrate and 
ADP are available. State 3 corresponds to the maximal physiological rate of ATP production and O2 
consumption. Under non-stimulated physiological conditions only 35% of the ATP-producing capacity 
is used [90]. Boveris et al. proposed a new concept of regulation of cellular respiration that depends on 
energy demands, which is controlled by the availability of ADP to F1-ATPase and of O2 and NO to 
cytochrome c oxidase [3]. 
The influence of NO on mitochondrial respiratory chain can be summarized as follow: (a) NO 
inhibits cytochrome c oxidase activity by competing with oxygen; (b) NO inhibits electron transfer 
between cytochrome b and c and increases mitochondrial production of O2−; and (c) NO inhibits 
electron transfer and NADH-dehydrogenase function in Complex I [3]. 
4.2. NO Inhibits Cytochrome c Oxidase Activity  
NO was first recognized as an inhibitor of mitochondrial electron transfer in 1994 [91,92], with the 
observations that low NO concentrations was able to reversibly inhibit brain and muscle cytochrome c 
oxidase through competitive binding at O2 site. This NO binding occurs at physiological 
concentrations of NO and inhibits the electron flow in the respiratory chain and therefore decreases O2 
consumption and ATP formation [2,93]. Differently from O2, NO reversibly binds to both reduced and 
oxidized cytochrome c oxidase. At low O2 concentration, NO binds to the heme a3 domains of reduced 
form of cytochrome c oxidase, as a competitive inhibitor of O2. However, at high O2 level, NO binds 
to the oxidized cytochrome c oxidase, via the copper moiety of the binuclear center instead of the iron 
moiety. This reaction results in nitrite (NO2−) formation and consequently in O2 consumption [94]. A 
persistent inhibition of cytochrome c oxidase can promote, at an early stage, the release of small 
amount of hydrogen peroxide, acting as cellular signaling defense molecule. But at a later stage, high 
concentrations of hydrogen peroxide may lead to peroxynitrite generation and induce apoptosis or 
necrosis [82]. 
4.3. NO Inhibits Electron Transfer between Cytochrome b and c  
Another NO sensitive site in the respiratory chain is the electron transfer at complex III,  
ubiquinol-cytochrome c reductase [3,90]. NO is able to inhibit succinate-cytochrome c reductase and 
NADH-cytochrome c reductase, with similar effect on both reductases but in a lower extent than 
cytochrome c oxidase [95]. Inhibition at this site increases the production of O2− and H2O2, which are 
not only involved with oxidative damage, but together with NO, are considered as part of an integrated 
system of mitochondrial signaling for cellular regulation [82].NO is also able to reduce cytochrome b, 
probably by its interaction with an iron-sulfur center, which is reversible but is not affected by the 
O2/NO ratio [3].  
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4.4. NO Inhibits Electron Transfer and NADH-Dehydrogenase Function in Complex I  
It has been shown that prolonged exposure of NO also leads to inhibition of complex I activity in 
murine macrophage cultured cells, with a concomitant decrease in the content of intracellular reduced 
glutathione [96]. At first this inhibition is reversible but it becomes persistent with time. The 
mechanisms of complex I inhibition are not completely clear. There are a few hypothetical 
mechanisms but three are the most likely: S-nitrosation, tyrosine nitration and damage to Fe–S  
centers [97]. S-nitrosation was suggested as an important mechanism of complex I inhibition because 
the inhibition was reverted by either light or reduced thiols, which are treatments that typically revert  
S-nitrosation [96,98]. Rat mitochondria from different tissues such as heart, liver and brain, exhibited 
inhibition of complex I after prolonged exposure to NO. The same effect was obtained after addition of 
peroxynitrite with tyrosine nitration, suggesting that tyrosine nitration induced by peroxynitrite would 
be one of the mechanisms involved in complex I inhibition [99]. This idea is supported by the finding 
of tyrosine nitration in Complex I subunits of bovine and human mitochondria after exposure to 
peroxynitrite [100]. 
It was hypothesized that inhibition of complex I, II and aconitase induced by NO could be caused 
by damage to iron-sulfur clusters and release of iron from these centers. NO would react directly with 
the iron, displacing elemental sulfur or cysteine residues [97]. However, Pearce et al. (2005) did not 
find any effect of NO and peroxynitrite on the cofactors of complex I and III (hemes, iron-sulfur 
cluster or flavin) [101]. The same result was found with Complex II, with the exception of the cofactor 
in aconitase, thus it was suggested that mammalian mitochondrial iron-sulfur cluster are resistant to 
degradation from oxidative/nitrosative stress [97,101,102]. 
5. NO and Mitochondrial Biogenesis 
NO plays an important role in mitochondrial biogenesis of skeletal muscle [88]. Several studies 
have shown that treatment of cells with NO donor increase mitochondrial markers, demonstrating 
induction of biosynthesis of functional mitochondria able to generate ATP via oxidative 
phosphorylation [5,103,104]. Treatment of rat primary skeletal muscle cultures with the NO donor  
S-nitroso-N-acetylpenicillamine (SNAP) led to a significant increase in mitochondrial content [27], a 
phenomenon also observed in other tissues. For example, studies performed in the primary cultures of 
brown adipocytes, which express a larger number of mitochondria than other cell types, have shown 
that incubation with SNAP increases the mitochondrial size and mitochondrial DNA (mtDNA) content 
in a concentration dependent manner [4]. The inductive effect of SNAP was completely abolished by 
supplementation of the medium with the NO scavenger oxyhemoglobin, indicating that the stimulatory 
effect depends on generation of NO.  
The exact molecular pathways involved in mitochondrial proliferation in response to NO signaling 
are not entirely understood, but in many tissues and cells, they have been associated to peroxisome 
proliferator-activated receptor gamma coactivator-1 (PGC-1α) [5,103,104] (Figure 3). In brown 
adipocyte tissue, NO-induced mitochondrial biogenesis is mimicked by incubation of cells with  
8-Br-cGMP, indicating that it depends on activation of guanylil cyclase and generation of guanosine 
3',5'-monophosphate (cGMP). The downstream mechanism requires induction of PGC-1α expression 
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since PGC-1α antisense oligomers reduced the SNAP-dependent increase in mtDNA content [4]. In 
addition, ectopic expression of PGC-1α into skeletal muscle cell lineage C2C12 induces a 2-fold 
increase in mtDNA content which was associated to a parallel increase (~60%) in mitochondrial 
density (mitochondrial number/cytoplasmic area) [105]. The PGC-1α-dependent increment in 
mitochondrial biogenesis occurs in parallel with increase in the basal oxygen consumption and in the 
expression (transcripts/proteins) of respiratory chain components, including the nuclear-encoded 
cytochrome c oxidase subunit IV and the mitochondrial-encoded cytochrome c oxidase subunit II and 
cytochrome c [105]. 
Figure 3. Schematic diagram illustrating the major NO pathways in the activation of 
mitochondrial biogenesis. Intracellular calcium release activates calcium/calmodulin kinase 
II (CaMK) triggering sequential activation of NOS and guanylate cyclase (GC) to generate 
cyclic GMP, which in turn activates protein kinase A (PKA). PKA phosphorylates CREB1 
allowing its nuclear translocation and activation of the PGC-1 gene (peroxisome 
proliferator-activated receptor gamma co-activator 1), a co-activator for NRF-1 (nuclear 
respiratory factor-1), a transcription factors for mitochondrial biogenesis. The NOS-dependent 
induction of mitochondrial biogenesis also involves activation of AMP-activated kinase 
(AMPK), allowing phosphorylation of PGC-1.  
 
Stimulation of mitochondrial biogenesis by NO also requires the expression of transcriptional 
factors, that include CREB1 (cAMP response element-binding protein 1) and the nuclear respiratory 
factors 1 and 2 proteins (NRF-1 and NRF-2), which mediate expression of multiple nuclear  
genes encoding for mitochondrial proteins, such as the mitochondrial rate-limiting enzyme for  
heme biosynthesis, 5-aminolevulinate synthase [106] and, the subunits of the respiratory chain  
complexes [107].  
This process involves an orchestrated cascade of phosphorylation events performed by distinct 
serine/threonine kinases. For example, while both serine/threonone kinases Akt [108] and PKA (cyclic 
AMP-dependent protein kinase) are able to activate eNOS via phosphorylation of Ser1177, leading to 
increased production of NO, phosphorylation of CREB transcription factor by PKA results in 
increased expression of PGC-1α, which in turn increases mitochondrial biogenesis. Actually, the most 
potent activator of PGC-1α transcription is the coactivator of CREB, named TORC1 (transducer of 
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regulated CREB binding protein 1). According to Wu el al. (2006) [109], TORC 1, 2 and 3 markedly 
increases PGC-1α promoter activity, in a CREB-dependent fashion in primary mouse skeletal muscle 
cultures. The authors have shown that transduction of mouse primary myotubes with an adenovirus 
expressing hTORC1, hTORC2, hTORC3 resulted in increased mRNA levels of PGC-1α and 
mitochondrial markers Cyt c, Cox II, and IDH3α (isocitrate dehydrogenase 3α). In addition, Akt may 
form a physical complex with PKA serving as a substrate of PKA [110]. Once phosphorylated, Akt 
activates eNOS, leading to increased NO production. Conversely, Akt may induce mitochondrial 
biogenesis through the phosphorylation of NRF-1 and CREB1, enabling their nuclear translocation and 
activation of target genes, such as mitochondrial transcription factor A (Tfam), which is required for 
mtDNA transcription and replication [111] (for review, see [112]). 
The molecular mechanisms of NO-dependent regulation of PGC-1α/ mitochondrial biogenesis also 
involve 5'-AMP-activated protein kinase (AMPK), a heterotrimeric kinase allosterically activated by 
AMP and inhibited by ATP, which serves as an energy sensor, under conditions of low energy charge 
(decrease in ATP and increase in AMP). Thus, conditions that cause significant cellular energy stress, 
such as exercise, starvation or mitochondrial dysfunction are able to increase AMPK activity (for 
review, see [113]) and promote mitochondrial biogenesis [114–116]. For example, exercise training 
performed in rat or humans increases mitochondrial content and capacity [117–119]. In fact 
contraction induced by electrical stimulation of isolated rat skeletal muscle also increases NO release 
from muscle [120] with a significant contribution of both calcium-calmodulin-dependent isoforms of 
NOS, nNOS and eNOS [121]. In working tissues, such as skeletal and cardiac muscle, increased levels 
of intracellular calcium during contraction have been associated to physiological induction of 
mitochondrial biogenesis. Intermittent exposure of L6 myotubes to the Ca2+ ionophore ionomycin  
(5 h/day) or to caffeine or W7, which release Ca2+ from the sarcoplasmic reticulum induced an 
increase in mitochondrial enzymes [122]. Interestingly, skeletal muscles from transgenic mice that 
selectively express a constitutively active form of calcium/calmodulin-dependent protein kinase IV 
showed augmented mtDNA replication and mitochondrial biogenesis. These effects are associated to 
up-regulation of mitochondrial enzymes involved in fatty acid metabolism and electron transport, and 
reduced susceptibility to fatigue during repetitive contractions. In mice C2C12 myotubes, the effect  
of CaMK was associated to activated the PGC-1α gene promoter and increased expression of  
PGC-1α [123]. Thus, calcium-regulated signaling pathways are able to induce mitochondrial 
biogenesis via activation of NOS or stimulation of Ca2+-dependent transcription factors. Interestingly, 
during exercise in humans, AMPK phosphorylates skeletal muscle nNOSµ at Ser1451 [124], which 
may account for the increase in glucose uptake during exercise. Indeed, taking into account that 
AMPK is able to phosphorylate and activate eNOS/nNOS during contracting human skeletal  
muscle [125], these data suggest that phosphorylation of NOS by AMPK may be, at least in part, 
involved in mitochondrial biogenesis in muscle cells.  
This correlation of AMPK, PGC-1α, NO and mitochondrial biogenesis in L6 myogenic cell lineage 
was recently confirmed by McConell et al. [103]. Incubation of L6 myotubes with AICAR, which 
activates AMP-activated protein kinase (AMPK), increased myotube mitochondrial biogenesis. The 
AMPK activator also increased the expression of PGC-1α, subunits I and IV of cytochrome c oxidase. 
Actually, while SNAP increased phospho-AMPK and markers of mitochondrial biogenesis (PGC-1α, 
NRF-1, COX-1 and COX-4), inhibition of NOS with L-NAME attenuated the AICAR-induced 
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increases in COX-1 and COX-4 protein, indicating that activation of AMPK in L6 myotubes increases 
mitochondrial biogenesis, at least in part, via interactions with NOS. 
6. NO and Myogenic Differentiation 
Differentiation of embryonic muscle cells involves fusion of mononucleated myoblasts derived 
from pluripotent mesodermic cells to form multinucleated myotubes. Myotubes differentiate into 
mature skeletal muscle fibers with functional contractile apparatus and compartmentalized expression 
of synaptic proteins [126]. Beyond this stage, mitosis and DNA synthesis arrest almost completely and 
generation of new fibers depends on quiescent precursor cells named “satellite cells”, located under the 
basal lamina of individual postnatal and adult myofibers.  
Both embryonic and adult myogenic cells are influenced by changes in NO levels. While embryonic 
myoblasts have NOS activity, as measured by their ability to convert arginine to citrulline [127], adult 
satellite cells are activated by nitric oxide (NO) produced in muscle fibers, which may contribute to 
post-injury regeneration of skeletal muscle. According to Lee et al. [127] NOS activity dramatically 
increases in chick embryonic myoblasts that are competent for fusion, and coincides with increment in 
intracellular cGMP levels. The authors also showed that while NO donor SNP (sodium nitroprusside) 
accelerated myoblast fusion, the NOS inhibitor L-NMMA (NG-methyl-L-arginine) delayed the fusion 
that is reversed by treatment with 8-Br-cGMP, an analog of cGMP. 
Differentiation of myogenic cell also requires mitochondrial elongation that depends on the cellular 
generation of NO. Using myogenic precursor cells isolated from the muscles of newborn mice, De 
Palma et al. [128] showed that inhibition of NO synthesis lead to inhibition of both mitochondrial 
elongation and myogenic differentiation. This phenomenon was associated with NO-dependent 
inhibition of dynamin-related protein-1 (Drp1) [128], a GTPase protein that induces mitochondrial 
fission and, as consequence, interferes with maintenance of mitochondrial integrity (for review  
see [129–131]. By inhibiting Drp1, NO increases the formation of mitochondrial network, due to the 
ongoing mitochondrial fusion, and stimulates myogenic differentiation.  
A better understanding of NO interference on myogenic differentiation may be of crucial 
importance to development of new therapeutic strategies for enhancing skeletal muscle mass and 
performance, opening promising perspectives for treatment of conditions associated with reduced 
proliferation of myogenic cells, such as aging or degenerative diseases.  
7. Potential Therapeutic Strategies 
Several drugs with NO-donating properties are currently in use in clinical practice, mostly for 
cardiovascular diseases, such as nitrovasodilator, drugs affecting NOS mRNA and/or protein levels 
with special modulation of eNOS [7]. A specific treatment of muscle diseases based on NO physiology 
is still not available, however several strategies have been studied in recent years. Focusing on skeletal 
muscle and mitochondrial dysfunction, NO-directed approaches can be summarized in: diet, exercise 
and pharmacological approaches to increase NO in subcellular compartments [132]. The main 
objective when focusing on mitochondrial deficiencies is to increase the energy supply by improving 
the oxidative phosphorylation efficiency or increasing mitochondrial content.  
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It has been shown that calorie restriction lowers whole-body energy expenditure and induces 
mitochondrial biogenesis in overweight non-obese humans [133]. This study also demonstrated a 
decrease in DNA damage and proposed that caloric restriction would induce biogenesis of “efficient” 
mitochondria in human skeletal muscle as an adaptive mechanism, reducing oxidative stress.  
Calorie restriction was also able to increase mitochondrial biogenesis, eNOS expression and Akt 
phosphorylation in mice skeletal muscle, indicating that the NO pathway is activated [134]. 
Several studies using rodent models have shown that exercise training induces an increase in 
skeletal muscle mitochondrial content [135], which was demonstrated by increased expression of 
mitochondrial markers. As discussed in section 5, the mechanism of exercise induction of 
mitochondrial biogenesis involves the PGC-1α pathway [136]. It is suggested that the source of NO in 
exercise induced mitochondrial biogenesis is eNOS, as Nisoli et al. (2004) [104] reported that  
eNOS −/− mice had reduced mitochondrial content in skeletal muscle. However, Wadley et al. (2007) 
could not confirm the involvement of either eNOS or nNOS in the exercise induced mitochondrial 
biogenesis, studying eNOS −/− and nNOS −/− mice [135]. Later, Lee-Young et al. (2010) showed that 
eNOS is critical to muscle cell signaling during exercise in vivo, by showing that ablation of eNOS in 
eNOS −/− mice resulted in impaired exercise capacity [137]. Studies evaluating the exercise training in 
patients with mitochondrial myopathy, a genetic disorder with oxidative phosphorylation deficiency, 
aim the stimulation of mitochondrial biogenesis and a gene shifting, with increase of mitochondrial 
content with normal mtDNA [138–140]. In fact, improvement of muscle strength and oxidative 
capacity have been demonstrated after exercise training [140] but further investigations are still needed 
to determine the safety, effective benefits and the most appropriate exercise training protocol.  
Supplementation with arginine or citrulline has also been proposed for treatment of mitochondrial 
disorders with NO deficiency [141]. L-arginine was first used in the treatment of a mitochondrial 
encephalopathy with stroke like syndrome (MELAS) as an NO precursor with the objective to promote 
vasodilation in cerebral vessels [142,143]. The rationale of this approach is that patients with MELAS 
probably have a deficiency in smooth muscle vascular relaxation, which could be responsible for the 
symptoms of cerebral ischemia. This therapeutic approach is supported by the finding of low levels of 
serum arginine [142], low levels of citrulline [144] and endothelium dysfunction [145] in patients with 
MELAS. This treatment showed promising results with significant decrease in stroke frequency, 
improvement of neurological deficits [142,143,145,146] and increased NO production [147]. Based on 
these findings and the observation of NO deficiency in muscle fibers with cytochrome c oxidase 
deficiency of patients with mitochondrial myopathy [27], it was proposed that arginine and citrulline 
supplementation could have a broader application in mitochondrial diseases, especially in those with 
muscular symptoms [141].  
Mitochondrial biogenesis can also be activated with the use of drugs, such as resveratrol  
(3,5,4'-trihydroxystilbene), a diet-derived polyphenol. Treatment of rodents with resveratrol induced 
increased mitochondrial content and improved function in skeletal muscle [148,149]. The mechanism 
of action involves the decrease in PGC-1α acetylation with resulting increase in PGC-1α activity [148] 
and AMPK activation [150]. Studies using endothelial cells demonstrated that resveratrol induces an 
up-regulation of eNOS [151]. Other drugs acting specifically on eNOS have been largely studied in 
cardiovascular diseases [132]. One example is statin that is classically known by the effects on 
dyslipidemia, however other beneficial pleiotropic effects have been reported [132]. Statin pleiotropic 
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effects are mainly reported in studies with endothelial cells showing that eNOS activity may be 
increased [152]. However, it is well known that statins, such as sinvastatin and atorvastatin, can induce 
myopathy with rhabdomyolysis. A recent study in mice has demonstrated that the treatment with a 
novel class of statin, an NO-donating atorvastatin was able to prevent the atorvastatin induced skeletal 
muscle dysfunction [153]. The authors showed that the NO-donating atorvastatin maintained the lipid 
lowering effect with absence of the other side effects observed with atorvastatin, such as sarcolemmal 
damage and mitochondrial dysfunction.  
NO-donating drugs have also been tested in Duchenne muscular dystrophy in order to improve 
muscle regeneration and restore NO intracellular level, which is diminished due to the loss of nNOS. 
Brunelli et al. [154] studied the treatment with HCT 1026, a derivative of flurbiprofen, a nonsteroidal 
anti-inflammatory drug, that releases NO and with no severe side effects. They showed that HCT 1026 
slowed down disease progression and ameliorated the morphological, biochemical and functional 
phenotype. In the same study arterially delivered donor stem cells in association with HCT 1026 
presented an enhanced therapeutic efficacy. This treatment demonstrated better results than the 
combination of L-arginine and deflazacort [155]. Recently, Buono et al. [156] demonstrated a 
therapeutic effect of molsidomine, another NO releasing drug, in dystrophic mice. This treatment 
increased regenerating muscle fibers, as well as led to functional amelioration of the muscle, due to 
increased proliferation of satellite cells. These studies open up a new possibilities for treatment of 
muscle diseases including those with mitochondrial dysfunction, especially because they are drugs 
already tested in humans and could be used in long term treatments.  
8. Conclusions  
NO has important roles on the regulation of mitochondrial function and induction of mitochondrial 
biogenesis. The pathways involved in NO signaling are complex but an increasing number of articles 
have addressed this subject in recent years. Several therapeutic approaches have been proposed with 
the aim of increasing mitochondrial content to compensate mitochondrial deficiency and to increase 
energy supply. However a lot of work has to be done to elucidate the exact mechanisms involved to 
make this approaches viable for clinical practice. 
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